Structure Therapeutics (NASDAQ:GPCR) Stock Rating Lowered by Wall Street Zen

Structure Therapeutics (NASDAQ:GPCR) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Sunday.

A number of other brokerages have also issued reports on GPCR. Citizens Jmp cut their target price on Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating on the stock in a research report on Friday. Canaccord Genuity Group set a $111.00 price objective on Structure Therapeutics in a research note on Friday. Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday. HC Wainwright cut their price objective on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, June 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Structure Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $110.91.

Structure Therapeutics Price Performance

Shares of GPCR opened at $53.81 on Friday. The firm has a 50-day simple moving average of $47.94 and a two-hundred day simple moving average of $53.69. The stock has a market cap of $3.82 billion, a PE ratio of -53.81 and a beta of -1.43. Structure Therapeutics has a 1-year low of $16.00 and a 1-year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, sell-side analysts expect that Structure Therapeutics will post -1.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its holdings in shares of Structure Therapeutics by 18.5% during the second quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock worth $1,124,000 after purchasing an additional 8,444 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Structure Therapeutics by 7.6% in the 2nd quarter. Invesco Ltd. now owns 424,548 shares of the company’s stock valued at $8,805,000 after purchasing an additional 30,162 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Structure Therapeutics by 474.9% in the 2nd quarter. Marshall Wace LLP now owns 176,060 shares of the company’s stock valued at $3,651,000 after purchasing an additional 145,434 shares during the last quarter. Jump Financial LLC boosted its position in shares of Structure Therapeutics by 105.9% in the 2nd quarter. Jump Financial LLC now owns 63,234 shares of the company’s stock valued at $1,311,000 after purchasing an additional 32,524 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Structure Therapeutics in the 2nd quarter valued at about $3,480,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.